the safety and effectiveness of the current treatment regimen with or without roflumilast in advanced copd patients: a systematic review and meta-analysis of randomized controlled trials

Authors

saeideh jafari andarian tehran university of medical sciences, tehran, iran.سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences)

alireza olyaeemanesh national institute of health research, tehran university of medical sciences, tehran, iran.سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences)

seyed alireza hosseini office for clinical trials, food and drug organization, tehran, iran.

ali akbari sari department of health management and economics, and knowledge utilization research center, tehran university of medical sci-ences, tehran, iran.سازمان اصلی تایید شده: دانشگاه تهران (tehran university)

abstract

background: chronic obstructive pulmonary disease (copd) is a chronic respiratory disease, which reduces the lung function and causes respiratory symptoms over time, and it is primarily associated with shortness of breath, cough and sputum production. roflumilast, which is a long-acting selective inhibitor, reduces the anti-inflammatory effect of the main symptoms of copd. the aim of this study was to compare the clinical effectiveness of adding roflumilast to the current treatment regimen of patients with severe copd.   methods: to retrieve the marker studies, medical databases were searched up to february 2014. we included studies, which compared the clinical effectiveness and safety of roflumilast as concomitant to long-acting ß2-agonist/long-acting muscarinic antagonist (laba/lama) regimen, in adult patients with severe copd. the number of exacerbations, changes in the lung function fev1, fev1/fvc and quality of life were the major predefined outcomes. meta-analysis of outcomes was performed by the revman software, with i2> 50%, representing considerable heterogeneity.   results: seven randomized controlled trials and two systematic reviews were included. in terms of safety, participants were likely to experience more side effects from roflumilast compared to placebo, particularly gastrointestinal effects (diarrhea, nausea, vomiting), headache and weight loss. there was no significant difference in the risk of cardiac complications or flu-like symptoms or upper respiratory tract infection in the two groups. in terms of effectiveness, only a small improvement was observed in sgrq (st george's respiratory questionnaire) index. roflumilast reduced moderate to severe attacks, and caused significant improvements in the lung function regardless of the severity of the disease and the concurrent use of other standard copd therapies.   conclusion: roflumilast anti-inflammatory therapy reduces the chronic bronchitis symptoms in patients with moderate to severe copd, and it can be safely used with other drugs simultaneously.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials

  Background: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, which reduces the lung function and causes respiratory symptoms over time, and it is primarily associated with shortness of breath, cough and sputum production. Roflumilast, which is a long-acting selective inhibitor, reduces the anti-inflammatory effect of the main symptoms of COPD. The aim of ...

full text

The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials

BACKGROUND Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, which reduces the lung function and causes respiratory symptoms over time, and it is primarily associated with shortness of breath, cough and sputum production. Roflumilast, which is a long-acting selective inhibitor, reduces the anti-inflammatory effect of the main symptoms of COPD. The aim of this study ...

full text

Efficacy and safety of inhaler steroids in COPD patients: Systematic review and meta-analysis of randomized placebo-controlled trials

Background: Chronic obstructive pulmonary disease (COPD) is a major health dilemma and cause of morbidity and mortality in either industrialized or developing countries and inhaled corticosteroids are widely used worldwide in these patients. In this systematic review, we aimed to analyze the effectiveness of these gents compared to placebo. Methods: Pubmed and Google Scholar literature search ...

full text

A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing the Safety of Dapagliflozin in Type 1 Diabetes Patients

Background and Purpose: The dapagliflozin’s safety profile in insulin-treated adult type-1 diabetes mellites (T1DM) patients remains poorly explored. Therefore, this systematic review and meta-analysis compared the risk of all-cause side effects, study discontinuation of participants due to side effects, urinary tract infection (UTI), diabetic ketoacidosis, and hypoglycemia between dapagliflozi...

full text

Probiotics for the Treatment of Asthma: A Systematic Review and Meta-Analysis of Randomized Trials

Background: Asthma is a growing problem worldwide and the limitations of the current therapy for allergic asthma highlight the need for novel therapeutics. We conducted a systematic review and meta-analysis to find out the role of probiotics in the treatment of Asthma. <stron...

full text

My Resources

Save resource for easier access later


Journal title:
medical journal of islamic republic of iran

جلد ۳۰، شماره ۱، صفحات ۱۸۳-۱۹۸

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023